AMLX Stock Forecast 2025-2026
Distance to AMLX Price Targets
AMLX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Amylyx (AMLX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AMLX and similar high-potential opportunities.
Latest AMLX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, AMLX has a neutral consensus with a median price target of $10.00 (ranging from $3.00 to $12.00). Currently trading at $3.78, the median forecast implies a 164.9% upside. This outlook is supported by 3 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Fein at HC Wainwright & Co., projecting a 217.9% upside. Conversely, the most conservative target is provided by Graig Suvannavejh at Mizuho, suggesting a 20.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMLX Analyst Ratings
AMLX Price Target Range
Latest AMLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $12.00 |
| Dec 5, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $12.00 |
| Nov 18, 2024 | Baird | Joel Beatty | Outperform | Upgrade | $11.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $12.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $8.00 |
| Jul 12, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $4.00 |
| Jul 10, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $8.00 |
| Jun 24, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $8.00 |
| May 14, 2024 | Mizuho | Graig Suvannavejh | Neutral | Maintains | $3.00 |
| May 10, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $8.00 |
| Apr 11, 2024 | Baird | Joel Beatty | Neutral | Maintains | $3.00 |
| Apr 11, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $8.00 |
| Apr 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $8.00 |
| Mar 12, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $8.00 |
| Mar 11, 2024 | Deutsche Bank | Neena Bitritto-Garg | Buy | Maintains | $8.00 |
| Mar 11, 2024 | Baird | Joel Beatty | Neutral | Downgrade | $4.00 |
| Mar 11, 2024 | Leerink Partners | Marc Goodman | Market Perform | Downgrade | $0.00 |
| Mar 11, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Downgrade | $4.00 |
| Mar 8, 2024 | Mizuho | Graig Suvannavejh | Buy | Reiterates | $32.00 |
| Mar 8, 2024 | Evercore ISI Group | Umer Raffat | In-Line | Downgrade | $0.00 |
Amylyx Pharmaceuticals Inc. (AMLX) Competitors
The following stocks are similar to Amylyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amylyx Pharmaceuticals Inc. (AMLX) Financial Data
Amylyx Pharmaceuticals Inc. has a market capitalization of $334.92M with a P/E ratio of 2.5x. The company generates $87.37M in trailing twelve-month revenue with a -42.6% profit margin.
Revenue growth is -259.9% quarter-over-quarter, while maintaining an operating margin of +6,113.4% and return on equity of -100.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Amylyx Pharmaceuticals Inc. (AMLX) Business Model
About Amylyx Pharmaceuticals Inc.
Develops therapeutics for neurodegenerative diseases.
The company focuses on research and development of innovative therapeutics targeting conditions like ALS and Alzheimer's disease. It generates revenue through the advancement of its drug candidates that aim to modify disease pathways and provide neuroprotective effects, potentially leading to commercialization upon successful clinical trials.
Headquartered in the United States, Amylyx Pharmaceuticals plays a significant role in the healthcare sector, addressing critical unmet medical needs. The company's efforts contribute to the broader biotechnology industry's goal of improving patient outcomes and advancing medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
123
CEO
Mr. Joshua B. Cohen
Country
United States
IPO Year
2022
Website
amylyx.comAmylyx Pharmaceuticals Inc. (AMLX) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who purchased shares before November 11, 2022.
The investigation into Amylyx Pharmaceuticals may indicate potential legal issues, which could impact stock performance and investor confidence in the company.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who bought shares before November 11, 2022.
The investigation into Amylyx Pharmaceuticals may signal potential legal troubles or financial liabilities, impacting stock value and investor sentiment regarding the company.
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who purchased shares before November 11, 2022.
Potential legal claims against Amylyx could affect the company's stock performance, impacting investor sentiment and share value for those holding securities since before November 2022.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who bought shares before November 11, 2022.
The investigation into Amylyx Pharmaceuticals may signal potential legal issues or financial risks, impacting investor confidence and stock performance for those holding shares.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who bought shares before November 11, 2022.
The investigation into Amylyx Pharmaceuticals may indicate potential legal issues or financial instability, impacting investor confidence and stock performance.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Amylyx Pharmaceuticals (NASDAQ:AMLX) who purchased securities before November 11, 2022.
The investigation into Amylyx Pharmaceuticals may indicate potential legal issues or financial risks, affecting stock value and investor confidence.
Frequently Asked Questions About AMLX Stock
What is Amylyx Pharmaceuticals Inc.'s (AMLX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Amylyx Pharmaceuticals Inc. (AMLX) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $3.00.
Is AMLX stock a good investment in 2025?
According to current analyst ratings, AMLX has 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMLX stock?
Wall Street analysts predict AMLX stock could reach $10.00 in the next 12 months. This represents a 164.9% increase from the current price of $3.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amylyx Pharmaceuticals Inc.'s business model?
The company focuses on research and development of innovative therapeutics targeting conditions like ALS and Alzheimer's disease. It generates revenue through the advancement of its drug candidates that aim to modify disease pathways and provide neuroprotective effects, potentially leading to commercialization upon successful clinical trials.
What is the highest forecasted price for AMLX Amylyx Pharmaceuticals Inc.?
The highest price target for AMLX is $12.00 from Andrew Fein at HC Wainwright & Co., which represents a 217.9% increase from the current price of $3.78.
What is the lowest forecasted price for AMLX Amylyx Pharmaceuticals Inc.?
The lowest price target for AMLX is $3.00 from Graig Suvannavejh at Mizuho, which represents a -20.5% decrease from the current price of $3.78.
What is the overall AMLX consensus from analysts for Amylyx Pharmaceuticals Inc.?
The overall analyst consensus for AMLX is neutral. Out of 10 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are AMLX stock price projections?
Stock price projections, including those for Amylyx Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
